IRBT Investors Have Opportunity to Lead iRobot Corporation Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the 'Class Period'), of the important September 5, 2025 lead plaintiff deadline.
So What: If you purchased iRobot securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the iRobot class action, go to https://rosenlegal.com/submit-form/?case_id=23275 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) iRobot overstated the extent to which the Restructuring Plan would help iRobot maintain stability after the termination of the Amazon Acquisition; (2) as a result, it was unlikely that iRobot would be able to profitably operate as a standalone company; (3) accordingly, there was substantial doubt about iRobot's ability to continue as a going concern; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the iRobot class action, go to https://rosenlegal.com/submit-form/?case_id=23275 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/irbt-investors-have-opportunity-to-lead-irobot-corporation-securities-fraud-lawsuit-302520426.html
SOURCE THE ROSEN LAW FIRM, P. A.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Trump's Fed pick, Bank of England's 'hawkish' cut weigh on dollar
By Jaspreet Kalra and Ankur Banerjee SINGAPORE (Reuters) -The dollar was under pressure on Friday and was on course for a weekly fall as U.S. President Donald Trump's temporary choice for a fill-in Federal Reserve Governor stoked expectations for a dovish pick to replace chair Jerome Powell when his term ends. Sterling hovered near a two-week high, clinging to Thursday's sharp gains as the Bank of England cut interest rates but only after a narrow 5-4 vote, which showed the central bank's easing bias lacked conviction. Meanwhile, Trump's decision to nominate Council of Economic Advisers Chairman Stephen Miran to serve on a newly vacant seat at the Fed, while White House seeks a permanent addition, weighed on the dollar. Miran replaces Governor Adriana Kugler following her surprise resignation last week. "While we expect Miran to advocate for lower interest rates, we do not consider he will push the FOMC to cut the Funds rate if the data does not support a cut," said Joseph Capurso, head of international economics at the Commonwealth Bank of Australia. "Depending on the president's perception of his performance, he may also be a contender to replace Chair Powell when his term ends in May." Trump has repeatedly criticised Powell for not cutting interest rates, and while he has backed off threats to oust Powell before his term ends on May 15, has accelerated the search for a replacement. Fed Governor Christopher Waller is emerging as a top candidate to be the next chair, Bloomberg news reported on Thursday. Against a basket of peers, the dollar is down nearly 0.7% on the week so far as concerns over softening U.S. economic momentum, especially in the labour market, boosted hopes of Fed rate cuts. The dollar index was last at 98.04 in early trading on Friday. The Japanese yen was flat at 147.07 per dollar. Adam Grotzinger, senior fixed income portfolio manager at Neuberger Berman, expects four consecutive rate cuts from the Fed totalling 100 basis points, starting later this year and finishing early next year. "When we're looking at economic data, don't be surprised by softer prints coming in on the economy in Q3," Grotzinger said. "That said, for the full year we expect kind of an okay growth, but slower than the last couple years." Traders are pricing in a 93% chance of a rate cut in September with at least two rate cuts priced in by the end of the year. Atlanta Fed president Raphael Bostic said on Thursday that while risks to the job market have increased, it remains too soon to commit to rate cuts with more data lined up ahead of the Fed's policy review scheduled for September 16-17. The BOE's split vote on Thursday showed policymakers remained concerned about still high inflation, even as it cut rates. The pound was nearly flat at $1.3439 on Friday, holding the previous session's gains and on course to clock its best weekly performance since late June. The vote-split in the BoE meeting "implies one of the most hawkish versions of a 25bp cut that reasonable could have been expected," analysts at Goldman Sachs said. Elsewhere, the euro was perched near a two-week high as investors found comfort in the prospect of talks between the U.S. and Russia aimed at ending the war in Ukraine. Russian President Vladimir Putin and U.S. President Donald Trump will meet in the coming days, Kremlin aide Yuri Ushakov said on Thursday. This would mark the first summit between leaders of the U.S. and Russia since June 2021. With the Kremlin announcing summit plans, "geopolitics are in the spotlight and likely to be the major driver of FX markets heading into the weekend," analysts at ANZ wrote in a Friday note. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Bank of America Sees 5 Market Drivers in Play — and Suggests 2 Stocks to Buy
After a steady climb through much of July, the stock market has shown signs of cooling in early August. Mixed economic data, including a softer-than-expected jobs report, and renewed concerns about inflation have introduced a dose of caution among investors. Still, the broader uptrend is holding, with both the S&P 500 and Nasdaq in positive territory for the year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Against this backdrop, Bank of America sees five key factors aligning that could set the stage for the market's next leg higher. These include a 'political will' to drive short-term strength ahead of next year's midterm US elections; the impact of the recent 'Big Beautiful Bill' on U.S. manufacturing; the likelihood of substantial economic stimulus in Europe, particularly from Germany; a surge in capital expenditures on Wall Street, especially among the 'Magnificent 7' hyperscalers; and finally, BofA's proprietary 'regime indicator,' a historically accurate set of predictive signals that is starting to show signs of a recovery in the making. With those drivers potentially in play, BofA's analysts are sharpening their focus on the stocks they believe are positioned to ride the next wave. Two names in particular stand out, and we've turned to the TipRanks database to see what sets them apart. Let's dive in. Brown & Brown (BRO) We'll start in the insurance industry, where Brown & Brown is a specialist in risk management. The company has been in business since 1939 and is based in Daytona Beach, Florida. Brown & Brown offers policies across a wide range of categories, including property & casualty, employee benefits, and personal insurance. Its specialties span dealer services in the automotive industry, enterprise-scale risk solutions, and even tribal policies tailored to the specific needs of various Indian tribes. From those modest beginnings, Brown & Brown has evolved into a major industry player. It now employs over 17,000 people across more than 500 locations and has extended its presence to nearly 20 countries. Backed by $4.8 billion in annual revenue and a market cap exceeding $30 billion, the company is firmly established as a force in the global insurance landscape. Brown & Brown released its 2Q25 results on July 28, posting several encouraging data points. Quarterly revenue came in at $1.3 billion, slightly ahead of estimates and up 9.1% year-over-year. Adjusted diluted EPS also impressed, climbing 10 cents from the prior year to reach $1.03, 4 cents above consensus. However, those solid headline numbers weren't enough to satisfy the market. The stock fell as investors reacted to a weaker GAAP EPS of $0.78, down 13% from the year-ago quarter, and signs of margin compression. Organic revenue growth slowed to just 3.6%, raising questions about the quality of top-line expansion, which appeared heavily acquisition-driven. Broader industry challenges, such as softening insurance rates and mounting cost pressures, added to investor unease. For Bank of America analyst Joshua Shanker, this pullback may present a compelling entry point. He argues that Brown & Brown remains fundamentally strong, even if the stock has underperformed. 'BRO shares have fallen 26% since April 2, while the S&P 500 has appreciated 12%. This would represent one of the most significant periods of snap underperformance in BRO's history. The stock is now trading near trough valuations relative to the insurance broker peers whereas it has typically traded at a thick premium. Our EPS forecasts run ahead of consensus, and we believe that 2Q25 results have reset the outlook to a more steady-state growth rate. With material upside to our price objective, we believe investors should buy shares of Brown & Brown,' Shanker opined. That bullish stance is underscored by his new Buy rating and a $130 price target, implying a potential upside of ~42% over the next year. (To watch Shanker's track record, click here) Shanker's optimism aligns with a broader, albeit more cautious, sentiment on Wall Street. Brown & Brown has earned a Moderate Buy consensus rating based on 12 recent analyst reviews, which include 5 Buys, 6 Holds, and 1 Sell. The stock currently trades at $91.80, and the average price target of $111.40 suggests room for a 21% gain in the year ahead. (See BRO stock forecast) Surgery Partners (SGRY) The next BofA pick we'll look at, Surgery Partners, works as an adjunct in the healthcare field, providing surgical facilities and ancillary services in 200 locations in more than 30 states. The company acts as a link between providers and patients, offering expertise in general surgery, hand surgery, dermatology, oncology, plastic surgery, and anesthesia, to name just a few of the specialties available. The company got its start in 2004, and today works through a network of partnerships with healthcare systems, surgical hospitals, ambulatory surgery centers, and physician practices. Surgery Partners has more than 4,000 affiliated physicians, and sees more than 600,000 patients annually – and has achieved an impressive patient satisfaction rate of 94%. Surgery Partners went public in 2015, and since then has built itself up into a $2.87 billion player in the healthcare sector. Last year, the company brought in $3.1 billion in total revenue, a 13.5% gain from the $2.7 billion generated in 2023. The increase reflects rising demand for quality healthcare services. Looking at the company's most recent quarterly results, Q2 2025, Surgery Partners delivered $826.2 million in revenue, marking an 8.4% year‑over‑year increase, and slightly beating forecasts by $9.24 million. Adjusted EBITDA rose 9% to $129 million, yielding a 15.6% margin. The company posted an adjusted EPS of $0.17, exceeding analyst forecasts by $0.03. Despite these solid results, the stock has remained range-bound for most of the year, held back by concerns over slowing case volume growth and cautious full-year guidance. But for Bank of America analyst Joanna Gajuk, the current share price has opened a window of opportunity. 'We rate SGRY Buy given the strong tailwinds for Ambulatory Surgery Centers (ASCs) while the stock is trading at a depressed multiple: 10x 2026E EBITDA less NCI, below the historical average of 14x and below the 14x multiple on the recent ASC platform deal (AmSurg) takeout… Being a low-cost setting (40-50% lower vs inpatient), ASCs are the beneficiaries of payors (including Medicare) pushing utilization to outpatient. The aging demographics are also driving ASC vols (utilization increases with age). Meanwhile, ASCs are a lower capital intensity business compared to acute care hospitals, yielding higher returns on invested capital,' Gajuk noted. Her bullish stance is backed by a $28 price target, implying a potential one-year upside of ~25%. (To watch Gajuk's track record, click here) Overall, Wall Street echoes a similar sentiment. Surgery Partners holds a Moderate Buy consensus rating, based on 11 recent analyst reviews that break down to 8 Buys and 3 Holds. With shares currently trading at $22.41, the average price target of $30.90 suggests a potential gain of ~38% in the year ahead. (See SRGY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Susan Solves It: Betting on lower rates left homeowners paying the price
Homeowners who bought homes in recent years, betting on being able to refinance for a lower mortgage rate, didn't win big.
